Efficacy and safety of Stitivastatin 80 mg/day in hypercholesterolemic patients

Evan A. Stein, Michael H. Davidson, Adrian S. Dobs, Helmut Schrott, Carlos A. Duiovne, Harold Bays, Stuart R. Weiss, Michael R. Melino, Michael E. Stepanavage, Yale B. Mitchel

Research output: Contribution to journalArticlepeer-review

Abstract

This randomized, multicenter, double-blind parallel-group study was performed to evaluate the lipid-altering efficacy and safety of simvastatin 80 mg/day, a dose twice the current maximum recommended dose. At 20 centers in the United States, 521 male and female hypercholesterolemic patients were randomly assigned in a ratio of 2:3 to receive simvastatin 40 or 80 mg once daily, respectively, for 24 weeks in conjunction with a lipid-lowering diet. Patients met National Cholesterol Education Program (NCEP) low-density lipoprotein (LDL) cholesterol criteria for pharmacologic treatment. The mean percentage reductions (95% confidence intervals) from baseline in LDL cholesterol averaged at weeks 18 and 24 were 38% (-40 to -36) and 46% (-47 to -45) for the 40- and 80-mg groups, respectively (p <0.001 between groups). One third of patients on the 40- and 80-mg doses achieved an LDL cholesterol reduction of 46% and ≥53%, respectively. Decreases in apolipoprotein B, total cholesterol, and triglycerides were also significantly greater among patients receiving 80 mg/day. Simvastatin was well tolerated in both groups. Two patients (0.6%) in the 80-mg group developed myopathy. Consecutive, clinically significant hepatic transaminase elevations occurred in 3 (1.0%) and 6 (1.9%) patients in the 40- and 80-mg groups, respectively (p = 0.486). In conclusion, simvastatin 80 mg/day provided substantial reductions in LDL cholesterol, allowing most patients to reach their NCEP target levels; it also had an excellent safety and tolerability profile.

Original languageEnglish (US)
Pages (from-to)311-316
Number of pages6
JournalAmerican Journal of Cardiology
Volume82
Issue number3
StatePublished - Dec 1 1998
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Efficacy and safety of Stitivastatin 80 mg/day in hypercholesterolemic patients'. Together they form a unique fingerprint.

Cite this